200 related articles for article (PubMed ID: 21669212)
1. Tetrabenazine inhibition of monoamine uptake and methamphetamine behavioral effects: locomotor activity, drug discrimination and self-administration.
Meyer AC; Horton DB; Neugebauer NM; Wooters TE; Nickell JR; Dwoskin LP; Bardo MT
Neuropharmacology; 2011 Sep; 61(4):849-56. PubMed ID: 21669212
[TBL] [Abstract][Full Text] [Related]
2. GZ-11608, a Vesicular Monoamine Transporter-2 Inhibitor, Decreases the Neurochemical and Behavioral Effects of Methamphetamine.
Lee NR; Zheng G; Leggas M; Janganati V; Nickell JR; Crooks PA; Bardo MT; Dwoskin LP
J Pharmacol Exp Ther; 2019 Nov; 371(2):526-543. PubMed ID: 31413138
[TBL] [Abstract][Full Text] [Related]
3. GZ-793A, a lobelane analog, interacts with the vesicular monoamine transporter-2 to inhibit the effect of methamphetamine.
Horton DB; Nickell JR; Zheng G; Crooks PA; Dwoskin LP
J Neurochem; 2013 Oct; 127(2):177-86. PubMed ID: 23875622
[TBL] [Abstract][Full Text] [Related]
4. Effects of tetrabenazine on methamphetamine-induced hyperactivity in mice are dependent on order and time-course of administration.
Kuribara H
Pharmacol Biochem Behav; 1997 Jan; 56(1):9-14. PubMed ID: 8981603
[TBL] [Abstract][Full Text] [Related]
5. The vesicular monoamine transporter (VMAT-2) inhibitor tetrabenazine induces tremulous jaw movements in rodents: implications for pharmacological models of parkinsonian tremor.
Podurgiel SJ; Nunes EJ; Yohn SE; Barber J; Thompson A; Milligan M; Lee CA; López-Cruz L; Pardo M; Valverde O; Lendent C; Baqi Y; Müller CE; Correa M; Salamone JD
Neuroscience; 2013 Oct; 250():507-19. PubMed ID: 23867769
[TBL] [Abstract][Full Text] [Related]
6. Tetrabenazine, a vesicular monoamine transporter-2 inhibitor, attenuates morphine-induced hyperlocomotion in mice through alteration of dopamine and 5-hydroxytryptamine turnover in the cerebral cortex.
Kitanaka N; Kitanaka J; Hall FS; Kandori T; Murakami A; Muratani K; Nakano T; Uhl GR; Takemura M
Pharmacol Biochem Behav; 2018 Sep; 172():9-16. PubMed ID: 30017858
[TBL] [Abstract][Full Text] [Related]
7. meso-Transdiene analogs inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release.
Horton DB; Siripurapu KB; Norrholm SD; Culver JP; Hojahmat M; Beckmann JS; Harrod SB; Deaciuc AG; Bardo MT; Crooks PA; Dwoskin LP
J Pharmacol Exp Ther; 2011 Mar; 336(3):940-51. PubMed ID: 21177475
[TBL] [Abstract][Full Text] [Related]
8. The novel pyrrolidine nor-lobelane analog UKCP-110 [cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride] inhibits VMAT2 function, methamphetamine-evoked dopamine release, and methamphetamine self-administration in rats.
Beckmann JS; Siripurapu KB; Nickell JR; Horton DB; Denehy ED; Vartak A; Crooks PA; Dwoskin LP; Bardo MT
J Pharmacol Exp Ther; 2010 Dec; 335(3):841-51. PubMed ID: 20805303
[TBL] [Abstract][Full Text] [Related]
9. Identification of conformationally sensitive residues essential for inhibition of vesicular monoamine transport by the noncompetitive inhibitor tetrabenazine.
Ugolev Y; Segal T; Yaffe D; Gros Y; Schuldiner S
J Biol Chem; 2013 Nov; 288(45):32160-32171. PubMed ID: 24062308
[TBL] [Abstract][Full Text] [Related]
10. Role of vesicular monoamine transporter type 2 in rodent insulin secretion and glucose metabolism revealed by its specific antagonist tetrabenazine.
Raffo A; Hancock K; Polito T; Xie Y; Andan G; Witkowski P; Hardy M; Barba P; Ferrara C; Maffei A; Freeby M; Goland R; Leibel RL; Sweet IR; Harris PE
J Endocrinol; 2008 Jul; 198(1):41-9. PubMed ID: 18577569
[TBL] [Abstract][Full Text] [Related]
11. The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse.
Nickell JR; Siripurapu KB; Vartak A; Crooks PA; Dwoskin LP
Adv Pharmacol; 2014; 69():71-106. PubMed ID: 24484975
[TBL] [Abstract][Full Text] [Related]
12. The MAO-B inhibitor deprenyl reduces the oral tremor and the dopamine depletion induced by the VMAT-2 inhibitor tetrabenazine.
Podurgiel SJ; Yohn SE; Dortche K; Correa M; Salamone JD
Behav Brain Res; 2016 Feb; 298(Pt B):188-91. PubMed ID: 26590367
[TBL] [Abstract][Full Text] [Related]
13. Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2.
Nickell JR; Krishnamurthy S; Norrholm S; Deaciuc G; Siripurapu KB; Zheng G; Crooks PA; Dwoskin LP
J Pharmacol Exp Ther; 2010 Feb; 332(2):612-21. PubMed ID: 19855096
[TBL] [Abstract][Full Text] [Related]
14. Not All Antidepressants Are Created Equal: Differential Effects of Monoamine Uptake Inhibitors on Effort-Related Choice Behavior.
Yohn SE; Collins SL; Contreras-Mora HM; Errante EL; Rowland MA; Correa M; Salamone JD
Neuropsychopharmacology; 2016 Feb; 41(3):686-94. PubMed ID: 26105139
[TBL] [Abstract][Full Text] [Related]
15. N-terminus regulation of VMAT2 mediates methamphetamine-stimulated efflux.
Torres B; Ruoho AE
Neuroscience; 2014 Feb; 259():194-202. PubMed ID: 24321511
[TBL] [Abstract][Full Text] [Related]
16. The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats.
Beckmann JS; Denehy ED; Zheng G; Crooks PA; Dwoskin LP; Bardo MT
Psychopharmacology (Berl); 2012 Mar; 220(2):395-403. PubMed ID: 21938414
[TBL] [Abstract][Full Text] [Related]
17. Novel N-1,2-dihydroxypropyl analogs of lobelane inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release.
Horton DB; Siripurapu KB; Zheng G; Crooks PA; Dwoskin LP
J Pharmacol Exp Ther; 2011 Oct; 339(1):286-97. PubMed ID: 21778282
[TBL] [Abstract][Full Text] [Related]
18. Oral administration of GZ-793A, a VMAT2 inhibitor, decreases methamphetamine self-administration in rats.
Wilmouth CE; Zheng G; Crooks PA; Dwoskin LP; Bardo MT
Pharmacol Biochem Behav; 2013 Nov; 112():29-33. PubMed ID: 24075974
[TBL] [Abstract][Full Text] [Related]
19. New Scaffold for Lead Compounds to Treat Methamphetamine Use Disorders.
Lee NR; Zheng G; Crooks PA; Bardo MT; Dwoskin LP
AAPS J; 2018 Feb; 20(2):29. PubMed ID: 29427069
[TBL] [Abstract][Full Text] [Related]
20. A fluorescent-based assay for live cell, spatially resolved assessment of vesicular monoamine transporter 2-mediated neurotransmitter transport.
Bernstein AI; Stout KA; Miller GW
J Neurosci Methods; 2012 Aug; 209(2):357-66. PubMed ID: 22698664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
